Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | GHSR | Q92847 | 4/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.43 |
| ▸ | ITGAV | P06756 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795533 | 0.89 | MAPT (0.50) | MAPTSMN1; SMN2KDM4ECA12CA1 | |
| SCHEMBL14186058 | 0.89 | MAPT (0.50) | MAPTSMN1; SMN2KDM4ECA12CA1 | |
| SCHEMBL4954940 | 0.83 | MAPT (0.42) | MAPTSMN1; SMN2KDM4ECA12CA1 | |
| SCHEMBL24106585 | 0.82 | ITGB3 (0.50) | MAPTSMN1; SMN2KDM4EGHSRITGB3 | |
| SCHEMBL25132977 | 0.79 | ITGB3 (0.52) | MAPTSMN1; SMN2KDM4ECA12CA1 | |
| SCHEMBL7785677 | 0.77 | ITGB3 (0.51) | MAPTSMN1; SMN2KDM4EGHSRITGB3 | |
| SCHEMBL7785678 | 0.77 | ITGB3 (0.51) | MAPTSMN1; SMN2KDM4EGHSRITGB3 | |
| SCHEMBL14501719 | 0.77 | CA1 (0.38) | MAPTSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL4598418 | 0.76 | MEN1 (0.48) | MAPTSMN1; SMN2 | |
| SCHEMBL4598417 | 0.76 | MEN1 (0.48) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7304037-B2 | Cytostatic conjugates with integrin ligands | BAYER AKIENGESELLSCHAFT (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7304037-B2 | Cytostatic conjugates with integrin ligands | BAYER AKIENGESELLSCHAFT (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7304037-B2 | Cytostatic conjugates with integrin ligands | BAYER AKIENGESELLSCHAFT (DE) | 2007-12-04 | — | — | US | disclosed |
| EP-1347783-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20020193311-A1 | Novel cytostatic conjugates with integrin ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-12-19 | — | — | US | disclosed |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1238678-A1 | Enzyme-activated cytostatic conjugates with integrin ligands | Bayer Aktiengesellschaft (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002051444-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | ITGAV, ITGB3, ITGAL | MAPT 3777/4885SMN1; SMN2 2343/4885KDM4E 3669/4885 |
| US-20020193311-A1 | Novel cytostatic conjugates with integrin ligands | ITGB3, ITGAV, ITGB5 | MAPT 4656/4885SMN1; SMN2 3057/4885KDM4E 4532/4885 |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | ITGB3, ITGAV, ITGB5 | MAPT 4589/4885SMN1; SMN2 3190/4885KDM4E 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.